Japanese Billionaire Masayoshi Son’s Latest Portfolio: Top Stock Picks

In this article, we’ll look at billionaire Masayoshi Son’s portfolio management strategy as well as his approach to investing in the stock market. We’ll also take a look at Mr. Son’s top ten stock selections. To skip our in-depth discussion of Masayoshi Son’s investment philosophy and portfolio management strategies, go directly to Japanese Billionaire Masayoshi Son’s Latest Portfolio: Top 5 Stock Picks (in Japanese only).

Masayoshi Son, the chairman and CEO of Softbank, has been making headlines for the past decade as a result of his massive investments in startups. Mr. Son’s Japanese conglomerate, following the initial success of its $100 billion technology-focused Vision Fund, established Vision Fund 2 in 2019, with the goal of investing in companies that are developing artificial intelligence technologies. With profits down by 97 percent year on year in the December quarter of 2021, the Japanese conglomerate suffered a $3.5 billion loss in the September quarter of 2021, following two years of strong growth.

The substantial share price declines of several key portfolio technology companies, including Coupang, Inc. (NASDAQ:CPNG), Alibaba Group Holding Limited (NYSE:BABA), DiDi Global Inc. (NYSE:DIDI), and several new startups, were cited as the cause of the losses. Coupang, Inc. (NASDAQ:CPNG) made its public debut on the NASDAQ last year and is currently trading at a discount to its initial public offering price. As a result of the stock’s 60 percent decline in the past year, Alibaba Group Holding Limited (NYSE:BABA) has been one of billionaire Masayoshi Son’s worst-performing stock holdings over the past 12 months. The Japanese conglomerate owned a 25 percent stake in Alibaba Group Holding Limited as of December 2021, according to publicly available information (NYSE:BABA). Even worse, shares of Chinese ride-hailing giant DiDi have suffered a 71% decline in value over the past year.

SB Management, a wholly-owned subsidiary of Softbank, is another vehicle through which the Japanese billionaire invests in companies. SB Management is a small company when compared to his Vision Funds, with assets in its 13F portfolio totaling just over $1 billion as of December 31, 2021, according to the founder. SB management makes investments in early-stage companies and has primarily concentrated its investments in three industries: healthcare, technology, and financial services.

Lyell Immunopharma, Inc. (NASDAQ:LYEL), Revolution Healthcare Acquisition Corp. (NASDAQ:REVH), Sana Biotechnology, Inc. (NASDAQ:SANA), Compute Health Acquisition Corp. (NYSE:CPUH), and Sema4 Holdings Corp. are among the top ten stock holdings of the firm (NASDAQ:SMFR). SB Management’s top ten stock picks are all companies with a market capitalization under $500 million. When compared to larger companies, the upside growth potential of small-cap stocks is significantly greater. Additionally, small-cap companies stand a good chance of being acquired by larger corporations at a favourable price.

Our Methodology is as follows:

This analysis was conducted using SB Management’s 13F portfolio data, which was obtained from the fund’s most recent 13F filing with the SEC. The following is a list of Masayoshi Son’s top ten stock picks, as determined by the Japanese billionaire.

The latest portfolio of Japanese billionaire Masayoshi Son includes his top ten stock picks. Lyell Immunopharma, Inc. is a pharmaceutical company based in Lyell, Massachusetts (NASDAQ:LYEL)

The value of SB Management’s stake is $27 million.

2.67 percent of SB Management’s total portfolio is comprised of this company.

The following number of hedge funds are currently in operation: 10.

SB Management has held a position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) since the company’s initial public offering (IPO) on the NASDAQ in the second quarter of 2021. Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL), along with Coupang, Inc. (NASDAQ:CPNG), DiDi Global Inc. (NYSE:DIDI), and Alibaba Group Holding Limited (NYSE:BABA), have plummeted in value over the past two quarters, according to Bloomberg data.

Despite the sharp decline, the Japanese billionaire has maintained his holdings in the company for the past two quarters, according to publicly available information. As of December 2021, SB Management is the largest hedge fund owner of Lyell Immunopharma, Inc. (NASDAQ:LYEL) in our database, according to Insider Monkey. The company was also owned by a number of other elite funds, including Millennium Management and Citadel Investment Group, which were among the major shareholders.

Lyell Immunopharma, Inc. (NASDAQ:LYEL) is a biotechnology company that specialises in T-cell therapies that have the potential to cure patients suffering from solid tumours. Its T-cell therapy product pipeline includes a number of promising candidates, including LYL845 for the treatment of multiple solid tumours, LYL797 for the treatment of triple-negative breast cancers, and NY-ESO-1 for the treatment of synovial sarcoma.

Made for you: Bet of a Lifetime’s 10,000% Surge Made Indonesian Man a Billionaire

Despite the fact that shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) have been under pressure in recent quarters, market analysts appear to be optimistic about the company’s future prospects. In a research note issued today, Goldman Sachs set a bullish price target of $31 for Lyell Immunopharma, Inc. (NASDAQ:LYEL), representing a significant increase over the company’s current stock price of $6.50 per share. The consensus price target for the biotechnology company according to Wall Street analysts is $22.

Revolution Healthcare Acquisition Corporation (No. 9) (NASDAQ:REVH)

The value of SB Management’s stake is $29.22 million.

2.88 percent of SB Management’s total portfolio is comprised of this company.

The number of hedge fund investors is: N/A.

SB management has held shares of Revolution Healthcare Acquisition Corp. (NASDAQ:REVH) for the past three quarters, making it a part of the company’s portfolio. Revolution Healthcare Acquisition Corp. (NASDAQ:REVH) accounted for 2.88 percent of the firm’s 13F portfolio’s value as of the end of December, representing a $29.22 million stake at the time. Since the company’s initial public offering (IPO) on the NASDAQ in the first quarter of 2021, shares of Revolution Healthcare Acquisition Corp. (NASDAQ:REVH) have been under pressure.

Acquisition of assets and businesses by Revolution Healthcare Acquisition Corp. (NASDAQ:REVH), a company that specialises in business combinations such as acquisitions, mergers, stock purchases, and other similar transactions. The company is primarily concerned with identifying investment opportunities in the life sciences, healthcare, and technology sectors.

Sana Biotechnology, Inc. is the eighth company on the list (NASDAQ:SANA)

The value of SB Management’s stake is $34.1 million.

SB Management’s portfolio represents 3.38 percent of the total.

Number of hedge fund investors: eleven

With his holdings in companies such as Coupang, Inc. (NASDAQ:CPNG), DiDi Global Inc. (NYSE:DIDI), and Alibaba Group Holding Limited (NYSE:BABA), Japanese billionaire Masayoshi Son is one of the most significant investors in Sana Biotechnology, Inc. (NASDAQ:SANA). SB Management has held a position in Sana Biotechnology, Inc. (NASDAQ:SANA) for the past four quarters. Sana Biotechnology, Inc. As of December 31, there were 11 hedge funds holding long positions in Sana Biotechnology, Inc. (NASDAQ:SANA). In addition to SB management, Woodline Partners and Harvard Management Co. were among the company’s most important shareholders.

Sana Biotechnology, Inc. (NASDAQ:SANA) is a biotechnology company that specialises in the development and delivery of engineered cells as treatment options for patients. A number of product candidates, including SC291 are expected to be submitted as investigational new drug applications in 2022, according to Sana (CD19).

Sana Biotechnology, Inc. (NASDAQ:SANA) shares have also underperformed since the company’s initial public offering (IPO) on the NASDAQ in the first quarter of 2021. The company’s stock has dropped by nearly 80% since its initial public offering, and its market capitalization is currently hovering just over $1 billion.

Compute Health Acquisition Corp. is the seventh company on the list (NYSE:CPUH)

The value of SB Management’s stake is $38.9 million.

SB Management’s portfolio represents 3.84 percent of the total.

Holders of hedge funds number 66 in total.

As of December 31, SB Management owned 4 million shares of Compute Health Acquisition Corp. (NYSE:CPUH), representing a 3.84 percent stake in the company’s market capitalization and accounting for 3.84 percent of its 13F portfolio’s total value. Over the past three quarters, the firm’s stake in the company has remained unchanged. The stock of Compute Health Acquisition Corp. (NYSE:CPUH) has also struggled to generate positive momentum over the past few quarters, according to the company.

Compute Health Acquisition Corp. (NYSE:CPUH) was in 66 different hedge funds’ portfolios as of December 31, according to Insider Monkey’s tracking of 924 hedge funds that filed 13Fs for the quarter ended December 31. Aristeia Capital was the company’s largest shareholder, and SB management came in second place on the list of top stockholders.

CPUH (NYSE:CPUH) is a private equity firm that invests in businesses and assets through a variety of methods including mergers, acquisitions, stock purchases, and other similar business combinations. Healthcare businesses and companies in the medical device space, such as those involved in robotics and imaging, are the primary focus of the company.

Sema4 Holdings Corporation is ranked sixth (NASDAQ:SMFR)

The value of SB Management’s stake is $40.2 million.

SB Management’s portfolio represents 3.97 percent of the total.

The following number of hedge funds are in operation: 42.

Similarly to other top 10 stock picks, Sema4 Holdings Corp. (NASDAQ:SMFR) is a holding of Masayoshi Son’s Masayoshi Son Investments, which has held a stake in Sema4 Holdings Corp. (NASDAQ:SMFR) for the past two quarters. The stock of Sema4 Holdings Corp. (NASDAQ:SMFR) has dropped by approximately 80% in the last year, and it is currently trading at around $3 per share.

Sema4 Holdings Corp. (NASDAQ:SMFR) was established in 2017 as an artificial intelligence-driven genomic and clinical data intelligence platform company. It was recently named to Fast Company’s list of the world’s most innovative companies, which was published in September. Sema4 was named one of the most innovative companies in the data science category, and it was ranked third overall.

Sema4 Holdings Corp. (NASDAQ:SMFR) appears to be in the midst of a strong growth phase that could support its stock price in the long run, as the company has generated double-digit revenue growth over the past couple of quarters. Aside from that, the company’s aggressive growth strategies should help to further improve its financial performance in the years to come. In order to strengthen its AI-driven genomic and clinical data platform, Sema4 Holdings Corp. (NASDAQ:SMFR) intends to acquire GeneDx from Biogen. Business combination is expected to generate $350 million in pro forma revenue in 2022, according to estimates.

A number of elite funds have expressed optimism about the fundamentals of Sema4 Holdings Corp. (NASDAQ:SMFR). As of December 31, there were 42 hedge funds with long positions, up from 40 at the end of the previous quarter. Deerfield Management was the largest shareholder in the company, with a $62 million investment, followed by SB Management, which held a $22 million investment.

Sema4 Holdings Corp. (NASDAQ:SMFR) is a small company compared to larger companies such as Coupang, Inc. (NASDAQ:CPNG), DiDi Global Inc. (NYSE:DIDI), and Alibaba Group Holding Limited (NYSE:BABA). The company has a market capitalization of approximately $600 million.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Discover

Sponsor

spot_imgspot_img

Latest

DJI FPV DRONE HANDS-ON REVIEW

DJI has unveiled the DJI FPV drone, which delivers a submerged flight experience with ultra-wide 4K/60fps views and low-cache HD streaming. Suitable for all...

Scarlett Johansson’s Breast, Bra Size, and Body Statistics

Scarlett Johansson is one of the most well-known actresses in the world, with millions of fans all over the world. She is known as...

Oppo Find X3 Pro Review: China’s Biggest Phone Brand Has A New Flagship Phone

Chinese smartphone brand Oppo is on the rise. The Shenzhen-based company began the year with the introduction of a rolling phone that made headlines...

RESPAWN Gaming Chairs Review & Buyer’s Guide

In this RESPAWN gaming chairs review, we'll take a deep look at the most popular RESPAWN gaming chair models to see which is the...

KFC to Accept Dogecoin Payments As Cryptocurrency

The fast-food chain's official Twitter handle tweeted saying, "We accept cash, card, and dogecoin."Dogecoin, the meme cryptocurrency connected to a picture of a Shiba...